PCM
LSTA icon

Prelude Capital Management’s Lisata Therapeutics LSTA Stock Holding History

Prelude Capital Management’s Portfolio LSTA Stock Details LSTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-12
Closed -$15K – 1776
2013
Q3 		$15K Buy
+12
New +$13.3K ﹤0.01% 1233

Other funds holding LSTA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IHM
Iguana Healthcare Management New York $152M AUM 48.74% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SC
Sophrosyne Capital New York $11.5M AUM 17.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
DC
Deere & Company Moline, Illinois $140M AUM 16.7% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return

Prelude Capital Management's LSTA Position: Q4 2013 in Review

Prelude Capital Management sold out of Lisata Therapeutics (LSTA) in Q4 2013, closing a stake of 12 shares — an estimated $15K sold.

Prelude Capital Management first reported a position in LSTA in Q3 2013 and held it in 1 quarter. The position peaked at $15K in Q3 2013. 33 funds tracked by Wall St. Rank hold LSTA as of Q4 2013.

  • Prelude Capital Management reported no remaining Lisata Therapeutics position as of Q4 2013 after selling out during the quarter.
  • Prelude Capital Management sold 12 Lisata Therapeutics shares in Q4 2013, an estimated $15K.
  • Prelude Capital Management first reported a position in Lisata Therapeutics in Q3 2013 and held it in 1 quarter.
  • Prelude Capital Management's Lisata Therapeutics position peaked at $15K in Q3 2013.
  • 33 funds tracked by Wall St. Rank held Lisata Therapeutics as of Q4 2013.

Based on Prelude Capital Management's 13F filing for Q4 2013, filed 14 Feb 2014.